期刊文献+

乳铁蛋白对骨质疏松症大鼠创伤性骨关节炎的疗效 被引量:2

Therapeutic Effect of Lactoferrin on Traumatic Osteoarthritis Preceded by Osteoporosis
下载PDF
导出
摘要 目的:研究乳铁蛋白(LF)对患有骨关节炎的骨质疏松大鼠的软骨及软骨下骨的作用。方法:将40只雌性SD大鼠随机分为4组:骨关节炎组,骨关节炎乳铁蛋白治疗组,关节炎及骨质疏松组,骨关节炎及骨质疏松乳铁蛋白治疗组,每组各10只,双侧卵巢切除或假手术,12周后手术建立膝关节创伤性骨关节炎模型,根据分组不同给予LF(85mg/kg·d-1)或安慰剂。8周后取大鼠胫骨近端进行组织学检测、micro-CT、免疫组织化学染色、RTPCR、western blot评价。结果:LF的作用主要体现在OVX大鼠中,与对照组相比,LF干预组软骨下骨组织BV/TV增加了30.2%,Tb.Th增加了33.7%,Tb.Sp减少了50.1%;LF干预还降低了MMP-13和TRAP的mRNA及蛋白表达,增加了Runx2的mRNA及蛋白表达增加。结论:乳铁蛋白可以缓解OVX大鼠的创伤性骨关节炎,这种效果可能与LF对软骨下骨的作用间接相关,或者与LF降低MMP-13和TRAP表达的作用直接相关。 Objective:To evaluate whether Lactoferrin(LF)has a therapeutic effect on cartilage and subchondral bone in osteoporotic(OP)rats with osteoarthritis(OA).Methods:Forty female Sprague Dawley rats were stratified into four groups with 10 animals per group:OA,OA+LF,OP+OA,OP+OA+LF.OA was induced 12 weeks after bilateral ovariectomy(OVX)or sham operation.LF dissolved in 2ml 0.9% normal saline was administered by oral gavages at a dose of 85mg/kg/d,starting from the first day after the induction of OA.After 8-week treatment,the proximal tibia was harvested for histology,micro-computed tomography(micro-CT),immunohistochemical staining,real-time polymerase chain reaction,as well as western blot evaluation.Results:Therapeutic effect of LF was mainly observed in OVX rats,which increased BV/TV by 30.2%,the Tb.Th by 33.7%,and decreased Tb.Sp by 50.1%in micro-CT analysis of the subchondral bone.LF treatment also decreased the mRNA and protein expression of matrix metalloproteinase-13(MMP-13)and tartrate-resistant acid phosphatase(TRAP),as well as increasing the mRNA and protein expression of runt-related transcription factor 2(Runx2)in OVX rats.Conclusion:LF treatment reduced traumatic osteoarthritis in OVX rats,which was possibly related to the beneficial effect of LF on subchondral bone tissue indirectly,or direct effect on cartilage by decreasing the expression of MMP-13 and TRAP.
出处 《口腔医学研究》 CAS CSCD 北大核心 2016年第6期564-569,共6页 Journal of Oral Science Research
基金 高等学校博士学科点专项科研基金(20130181130004)
关键词 乳铁蛋白 骨质疏松 骨关节炎 大鼠 创伤 Lactoferrin Osteoporosis Osteoarthritis Rat Trauma
  • 相关文献

参考文献11

  • 1Lohmander LS. What can we do about osteoarthritis [J]. Arthritis Res, 2000, 2∶95-100.
  • 2Oettmeier R, Abendroth K, Oettmeier S. Analyses of the tidemark on human femoral heads. II. Tidemark changes in osteoarthrosis-a histological and histomorphometric study in non-decalcified preparations [J]. Acta Morphol Hung, 1989, 37∶169-80.
  • 3王买全,王永功,彭利伟,李亚东.雷奈酸锶对骨质疏松时种植体骨结合的影响[J].口腔医学研究,2015,31(7):673-675. 被引量:1
  • 4Bellido M, Lugo L, Roman-Blas JA, et al. Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis [J]. Arthritis Res Ther, 2010, 12∶R152.
  • 5Nagasawa T, Kiyosawa I, Kuwahara K. Amounts of lactoferrin in human colostrum and milk [J]. J Dairy Sci, 1972, 55∶1651-9.
  • 6Grey A, Zhu Q, Watson M, et al. Lactoferrin potently inhibits osteoblast apoptosis, via an LRP1-independent pathway [J]. Mol Cell Endocrinol, 2006, 251∶96-102.
  • 7Guo HY, Jiang L, Ibrahim SA, et al. Orally administered lactoferrin preserves bone mass and microarchitecture in ovariectomized rats [J]. J Nutr, 2009, 139∶958-64.
  • 8Hayami T, Pickarski M, Zhuo Y, et al. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis [J]. Bone, 2006, 38∶234-43.
  • 9Nishio Y, Dong Y, Paris M, et al. Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene [J]. Gene, 2006, 372∶62-70.
  • 10Mader JS, Smyth D, Marshall J, et al. Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells [J]. Am J Pathol, 2006, 169∶1753-66.

二级参考文献8

  • 1马慧萍,贾正平,葛欣,陈克明.骨质疏松症的药物防治研究现状[J].中国药师,2004,7(10):816-818. 被引量:14
  • 2蒋晔,丁翔宇,蒋懿,郝福,李艳荣.雷尼酸锶药效学与药动学的研究进展[J].中国医院药学杂志,2006,26(2):197-199. 被引量:6
  • 3Hwang D, Wang HL. Medical contraindications to implant therapy :Part II : Relative contraindications E J3. Implant Dent, 2007, 16(1) : 13-- 23.
  • 4BornsteinM M, Cionca N, M ombeiliA. Systemic conditions and treatments as risks for implant therapy [J]. Int J Oral Maxillofac Implants,2009,24(1) : 12-- 27.
  • 5K asug iS. Dental implant treatment to osteoporosis patients [J]. ClinCalcium, 2006, 16(2) : 348-- 353.
  • 6Yunfeng Li, Ying Gao, Additive effects of estrogen replace- ment therapy and bisphosphonates on osseointegration of hydroxyapatite--coated itanium screws in ovariectomized rats [J]. Oral and maxillofacial implants, 2010, 109(5) : 700- 7O5.
  • 7Bonnel ye E, Chabadel A, Sal tel F, et al. Dual effect of strontium ranelate: stimuation of osteoblast differentiation and inhibition of osteoclast formation and resorption i n vitro [J]. Bone, 2008, 42(1) 129 -138.
  • 8Ammann P, Shen V, Robin B, et al. Strontium ranelate im- proves bone resistance by increasing bone mass and improving architecture in intact female rats [J]. Bone Miner Res, 2004, 19(12) : 2012--2020.

同被引文献36

引证文献2

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部